LifeMD, Inc. (NASDAQ:LFMD) CFO Sells $700,500.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CFO Marc David Benathen sold 50,000 shares of the company's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $14.01, for a total transaction of $700,500.00. Following the completion of the sale, the chief financial officer now directly owns 339,554 shares in the company, valued at approximately $4,757,151.54. The trade was a 12.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Marc David Benathen also recently made the following trade(s):

• On Monday, June 16th, Marc David Benathen sold 75,000 shares of LifeMD stock. The shares were sold at an average price of $13.09, for a total transaction of $981,750.00.

LifeMD Stock Performance

Shares of NASDAQ LFMD traded down $0.30 during trading hours on Friday, hitting $14.76. 2,834,496 shares of the stock were exchanged, compared to its average volume of 1,053,583. The company has a market cap of $670.84 million, a PE ratio of -43.41 and a beta of 2.42. The company's fifty day simple moving average is $9.78 and its two-hundred day simple moving average is $7.01. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $15.34.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to analyst estimates of $62.47 million. As a group, sell-side analysts expect that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Institutional Trading of LifeMD

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC acquired a new stake in LifeMD in the first quarter valued at approximately $35,000. CWM LLC boosted its position in LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after buying an additional 1,351 shares in the last quarter. ProShare Advisors LLC acquired a new stake in LifeMD in the fourth quarter valued at approximately $51,000. Oxford Asset Management LLP acquired a new stake in LifeMD in the fourth quarter valued at approximately $52,000. Finally, Balyasny Asset Management L.P. acquired a new stake in LifeMD in the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 35.52% of the company's stock.

Wall Street Analysts Forecast Growth

LFMD has been the topic of a number of research analyst reports. BTIG Research upped their target price on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday. B. Riley raised shares of LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of LifeMD in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 price target on shares of LifeMD in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.